Pay in 4 interest-free payments of $5.96 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
GLP-1 (Glucagon-Like Peptide-1) medications are becoming increasingly popular for managing type 2 diabetes and obesity
The first participant was enrolled on March 4, 2024, and the last participant completed enrollment on July 15, 2024
The basal insulin dose was decreased by 20% at randomization, and Victoza was initiated at 0.6 mg/day and was titrated to 1.2 mg and 1.8 mg over the course of 2-3 weeks based on tolerability and an average fasting plasma glucose goal of 110 mg/dL
Early signs of improvement in liver function Improvements begin relatively soon after starting treatment
There were more studies comparing GLP-1 and dementia risk than other anti-diabetic agents which may create publication bias
Their LillyDirect self-pay option brings costs down to $299 to $499 a month, depending on the dose
US$ 22.47
US$ 23.31
US$ 21.09
US$ 20.17
US$ 24.40
US$ 28.82
